From real estate to medical and even tech, if I had a spare $30,000, these are the ASX shares I'd add to my portfolio this week.
Image source: Getty Images
REA Group Ltd (ASX: REA)
REA shares closed 0.17% lower on Wednesday afternoon, at $180.04 a piece. The shares have dropped 2.75% so far in 2026 and are currently 25.94% below where they were this time last year.
The real estate advertising company's share price suffered a gradual but consistent decline after it appointed a new CEO in late-August. At the time, some brokers also said they think the stock was overpriced. In late August, Toby Grimm from Baker Young said he sees challenges ahead for REA and suggested selling while the stock trades above his valuation.
By the end of the year, REA shares had lost over 30% of their value.
But analysts are still pretty bullish on the shares. And I agree that there could be a decent upside ahead for REA in 2026.
REA's latest results show the business continues to grow with first quarter FY26 revenue up 4% and profit up 5%.
Most analysts have a buy or strong buy rating on the ASX 200 stock, with a maximum 12-month target price of $290. That implies a massive 61.08% upside for investors in 2026, at the time of writing.
Pro Medicus Ltd (ASX: PME)
Pro Medicus shares rose 0.58% at the close of the ASX on Wednesday, at $215 each. The shares are 2.58% lower for 2026 so far and 17.15% below where they were this time last year.
The medical imaging technology provider's shares peaked at around $330 per share in mid-July. They then tumbled over 33% by the close of 2025.
But the company's visage imaging platform appears to be becoming the system of choice for large hospital networks in the US. This is thanks to its speed, scalability, and cloud-based architecture. The company is gaining traction with long-term contracts, it has a strong earnings visibility, a growing pipeline of major contract wins, all against a backdrop of radiologist shortages. The stock is very much on my radar this week.
Analysts seem to be divided about the potential outlook for the stock. Data shows that 4 out of 7 analysts have a buy or strong buy rating on the ASX shares. The maximum 12-month target price is $350 per share, which implies a 62.79% upside ahead for investors in 2026, at the time of writing.
Xero Ltd (ASX: XRO)
Xero shares closed 1.36% higher on Wednesday afternoon, at $108.60 a piece. The ASX 200 stock is 2.36% lower for the year so far and 37.58% below where it was last year.
From US-acquisition news to lower-than-expected results, the company has faced a couple of headwinds this year. But I think the reaction was way overdone and the level of sell-off unfounded.
I actually think Xero shares could double this year.
According to TradingView data, most analysts (11 out of 14) are bullish on Xero shares for 2026.
The maximum 12-month target price is $228.85 a piece, which implies a huge 110.83% upside for investors at the time of writing.
UBS says that it is positive on the medium term growth outlook for Xero and believes the current share price is an "attractive buying opportunity". The broker has a $194 price target on the shares.
Meanwhile, Macquarie is more bullish on the stock. The broker has an outperform rating and $228.90 price target on the shares, saying the company is well-positioned for growth in the US.
